Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vimian Group AB ( (SE:VIMIAN) ) has provided an update.
Vimian Group AB has published its 2025 Annual Report, detailing its strategy, financial performance and governance structure, alongside extensive sustainability and risk reporting. The report highlights segment overviews, targets and performance metrics, climate and workforce disclosures, and confirms that the official, auditor‑reviewed Swedish ESEF version is the prevailing legal document, with a PDF available in both Swedish and English for shareholders and other stakeholders.
The Annual Report underscores Vimian’s combined focus on organic and acquisition-driven growth across its four animal health segments, while outlining its sustainability framework, double materiality assessment and compliance with evolving reporting standards such as CSRD. By integrating risk, sustainability and corporate governance into the Board of Directors’ report, the company aims to provide a comprehensive view of its operations, risk exposure and long-term value creation for investors and other market participants.
The most recent analyst rating on (SE:VIMIAN) stock is a Sell with a SEK25.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian Group AB operates in the animal health industry, focusing on improving animal health through science and technology. The company is organised into four segments – Specialty Pharma, MedTech, Veterinary Services and Diagnostics – and targets growth through both organic development and acquisitions in global veterinary and pet care markets.
Average Trading Volume: 295,775
Technical Sentiment Signal: Sell
Current Market Cap: SEK13.81B
For detailed information about VIMIAN stock, go to TipRanks’ Stock Analysis page.